Saul H. Rosenberg

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

Tumor Biology, Bcl-2 Family Proteins, Medicine +9

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 1.9K citations · Full text

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +11

The promise and peril of chemical probes

C.H. Arrowsmith, James E. Audia, Christopher P. Austin et al. · Nature Chemical Biology · 2015 · 836 citations · Full text